Previous 10 | Next 10 |
Epizyme (NASDAQ: EPZM ): Q1 GAAP EPS of -$0.39 beats by $0.05 . Revenue of $7.9M vs. consensus of $0.32M. Press Release More news on: Epizyme, Inc., Earnings news and commentary, Healthcare stocks news,
Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for Second Quarter and Fourth Quarter 2019, Respectively Updated Data from Tazemetostat Development Program to be Presented in the Second Quarter First Research Milestone Achieved in Worldwide Co...
Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today announced the closing of its two concurrent underwritten public offerings of 11,500,000 shares of its common stock and 350,000 shares of its non-voting Series A Convertible Preferred Stock, which ...
Epizyme (NASDAQ: EPZM ) is down 4% premarket on light volume in reaction to the pricing of its concurrent public equity offerings . More news on: Epizyme, Healthcare stocks news, Stocks on the move, Read more ...
Epizyme, Inc. (Nasdaq:EPZM), a late-stage company developing novel epigenetic therapies, today announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting Series A Convertible Preferred Stock. Ep...
Epizyme, Inc. (Nasdaq: EPZM), a late-stage company developing novel epigenetic therapies, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock in two concurrent but separate underwritten public offerings. The offerings are bein...
Epizyme ( EPZM ) is a clinical-stage biotechnology pharmaceutical company that could get its first drug approval from the FDA in the near future. I believe Epizyme is a strategic company for investors to acquire. Epigenetic therapies are likely to be major revenue and profit drivers in the c...
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the following March investor conferences: Cowen 39 th Annual Health Care Conference on Tuesday, March 12, 2019 at 11:20 a.m. E...
Epizyme Inc. (NASDAQ:EPZM) Q4 2018 Earnings Conference Call February 26, 2019 8:30 AM ET Company Participants Alicia Davis - IR Rob Bazemore - Chief Executive Officer Shefali Agarwal - Chief Medical Officer Matt Ross - Chief Strategy and Business Officer Conference Call Pa...
Epizyme ( EPZM ) Q4 results : Revenues: $9.7M. More news on: Epizyme, Healthcare stocks news, Earnings news and commentary, Read more ...
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...